KYMR
Kymera Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$126.63Close
$10.3BMarket cap
$58.66 – $127.3152-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 95 · stronger than 95% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high 1% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
1%
1wk
up 14.3%
price change
1mo
up 13.3%
price change
12-month return
up 106%
market up 11% ·
its own up 100%
F-score
3 / 9
Weak
Altman Z
36.92
Low risk
P/E
33.1×
price / earnings
PEG
1.41
P/E / EPS growth
P/B
6.5×
price / book
Earnings yield
down 3.5%
EBIT / enterprise value
Cheaper than
20%
of the market · expensive
Revenue growth
down 17%
year on year
EPS growth
—
latest quarter
Sales growth
down 100%
latest quarter · -566 pts
ROE
up 26%
return on equity
Free cash margin
down 598%
-$234.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- operating cash flow is negative
- profitability slipped from last year
- profits not fully backed by cash
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitable on its assets
- reduced long-term debt
- short-term liquidity improved
Trade setup
ATR%
4.7%
$5.98 a day · 2×ATR $114.67
RS
95 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.1×
vs 50-day average
Up/down volume
1.09
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 25.3% over the year, from 65m to 81m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Profit not backed by cash Reported profit of $311.4M came with -$232.9M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
- Revenue shrinking Revenue fell 16.7% over the year, from $47.1M to $39.2M.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+6% vs market2 sessions after results
Financials
- Gross 0%
- Net 794%
- Free cash -598%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Gross margin | — | — | 0% | 0% | 0% | 0% |
| Operating income | -$46.3M | -$100.5M | -$161.3M | -$165.5M | -$261.6M | -$349.4M |
| Net income | -$45.6M | $100.2M | $154.8M | $147.0M | $223.9M | $311.4M |
| Net margin | -134% | 138% | 331% | 187% | 476% | 794% |
| Earnings per share | -$2.63 | $2.09 | $2.87 | $2.52 | $2.98 | $3.69 |
| Free cash flow | $79.0M | -$130.5M | -$155.9M | -$137.3M | -$207.3M | -$234.3M |
| Free cash margin | 232% | -179% | -333% | -175% | -440% | -598% |
| Cash | $31.0M | $48.0M | $68.4M | $110.0M | $120.3M | $357.0M |
| Shareholders' equity | $283.9M | $459.6M | $490.2M | $395.0M | $835.6M | $1.6B |
| Shares outstanding | 44.48m | 51.54m | 55.04m | 55.59m | 64.89m | 81.32m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 27, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 25, 2026 | Regulation FD · Other events ↗ |
| Jun 24, 2026 | Shareholder vote ↗ |
| Jun 8, 2026 | Director or officer change ↗ |
| Apr 30, 2026 | Results ↗ |
| Mar 27, 2026 | Charter or bylaws ↗ |
| Feb 26, 2026 | Material agreement · Agreement ended · Other events ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Dec 10, 2025 | Material agreement · Other events ↗ |